Altered cellular immune response to vaccination against SARS-CoV-2 in patients suffering from autoimmunity with B-cell depleting therapy.
Autoimmunity
Covid-19
Ocrelizumab
Rituximab
T-cells
Vaccination
Journal
Microbes and infection
ISSN: 1769-714X
Titre abrégé: Microbes Infect
Pays: France
ID NLM: 100883508
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
26
09
2022
revised:
11
01
2023
accepted:
12
01
2023
medline:
18
4
2023
pubmed:
22
1
2023
entrez:
21
1
2023
Statut:
ppublish
Résumé
B-cell depleting therapies result in diminished humoral immunity following vaccination against COVID-19, but our understanding on the impact on cellular immune responses is limited. Here, we performed a detailed analysis of cellular immunity following mRNA vaccination in patients receiving B-cell depleting therapy using ELISpot assay and flow cytometry. Anti-SARS-CoV-2 spike receptor-binding domain antibody assays were performed to elucidate B-cell responses. To complement our cellular analysis, we performed immunophenotyping for T- and B-cell subsets. We show that SARS-CoV-2 vaccination using mRNA vaccines elicits cellular T-cell responses in patients under B-cell depleting therapy. Some facets of this immune response including TNFα production of CD4
Identifiants
pubmed: 36681177
pii: S1286-4579(23)00006-0
doi: 10.1016/j.micinf.2023.105103
pmc: PMC9850844
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105103Informations de copyright
Copyright © 2023 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no relevant financial or non-financial interests to disclose.
Références
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Nat Med. 2003 May;9(5):540-7
pubmed: 12692546
Int Rev Cell Mol Biol. 2018;341:125-168
pubmed: 30262031
J Allergy Clin Immunol. 2021 Mar;147(3):870-875.e1
pubmed: 33338534
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
J Virol. 2002 Feb;76(3):1071-6
pubmed: 11773383
Front Immunol. 2021 Dec 07;12:803742
pubmed: 34950155
Clin Infect Dis. 2014 Feb;58(3):309-18
pubmed: 24421306
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
J Clin Immunol. 2022 Jul;42(5):914-922
pubmed: 35366743
Clin Exp Immunol. 2006 Feb;143(2):305-13
pubmed: 16412055
Nat Immunol. 2021 Jul;22(7):809-819
pubmed: 34140679
Semin Immunol. 2012 Oct;24(5):331-41
pubmed: 22560929
Immunity. 2016 Jun 21;44(6):1379-91
pubmed: 27287409
Nature. 2021 Aug;596(7872):410-416
pubmed: 34252919
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Ann Rheum Dis. 2021 Dec;80(12):1537-1544
pubmed: 34226189
JAMA Neurol. 2021 Dec 1;78(12):1510-1514
pubmed: 34554197
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Ann Rheum Dis. 2021 Oct;80(10):1345-1350
pubmed: 34285048
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Ann Rheum Dis. 2016 Apr;75(4):748-54
pubmed: 25688074
Front Immunol. 2022 Sep 08;13:954936
pubmed: 36159874
Nat Immunol. 2022 Apr;23(4):543-555
pubmed: 35288714
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Sci Immunol. 2021 May 25;6(59):
pubmed: 34035118
Cell. 2022 Jul 7;185(14):2434-2451.e17
pubmed: 35764089
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279